Home Newsfeeds Wedbush Maintains Outperform on Geron, Raises Price Target to $6

Wedbush Maintains Outperform on Geron, Raises Price Target to $6

Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and raises the price target from $5 to $6.

byBenzinga Newsdesk

January 4, 2023

1 minute read

Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and raises the price target from $5 to $6.

News

Sanofi Research Demonstrates 9.3% Reduction In All-Cause Healthcare Resource Utilization Rates, Including 23.5% Decrease In Hospitalization For Dario Users

By Happy Mohamed

May 9, 8:34 AM

Retrospective cohort study presented at ISPOR analyzed real-world data of users and non-users of a digital health solution NEW YORK, May 9, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO)

DRIO

Landos Biopharma To Present New Data On Immunometabolism At The 19th Annual Congress Of The European Crohn’s And Colitis Organisation

By Benzinga Newsdesk

January 8, 9:26 AM

Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were

LABP

Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday

By Lisa Levin

July 17, 7:52 AM

Keybanc boosted the price target for Camping World Holdings, Inc. (NYSE: CWH) from $28 to $36. Keybanc analyst Noah Zatzkin maintained an Overweight rating. Camping World shares rose 1.4% to $32.04 in pre-market trading.

AXSM

General
News

Moderna CEO Highlights Promising Cancer Vaccine Data: ‘Think About The Number Of Lives That Can Be Impacted’

By Erica Kollmann

December 14, 5:03 PM

Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in

MRK

Wedbush Maintains Outperform on Geron, Raises Price Target to $6

Related Posts

Sanofi Research Demonstrates 9.3% Reduction In All-Cause Healthcare Resource Utilization Rates, Including 23.5% Decrease In Hospitalization For Dario Users

Landos Biopharma To Present New Data On Immunometabolism At The 19th Annual Congress Of The European Crohn’s And Colitis Organisation

Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday

Moderna CEO Highlights Promising Cancer Vaccine Data: ‘Think About The Number Of Lives That Can Be Impacted’